International Atomic Energy Agency-Sponsored multination study of intra-arterial rhenium-188-labeled lipiodol in the treatment of inoperable hepatocellular carcinoma: Results with special emphasis on prognostic value of dosimetric study Journal Article
| Authors: | Bernal, P.; Raoul, J. L.; Stare, J.; Sereegotov, E.; Sundram, F. X.; Kumar, A.; Jeong, J. M.; Pusuwan, P.; Divgi, C.; Zanzonico, P.; Vidmar, G.; Buscombe, J.; Chau, T. T. M.; Saw, M. M.; Chen, S.; Ogbac, R.; Dondi, M.; Padhy, A. K. |
| Article Title: | International Atomic Energy Agency-Sponsored multination study of intra-arterial rhenium-188-labeled lipiodol in the treatment of inoperable hepatocellular carcinoma: Results with special emphasis on prognostic value of dosimetric study |
| Abstract: | A multicenter study was sponsored by the International Atomic Energy Agency (IAEA) to assess the safety and efficacy of transarterial rhenium-188 (188Re) HDD lipiodol (radioconjugate to lipiodol using an HDD kit) in the treatment of unresectable hepatocellular carcinoma. During 5 years, 185 patients received at least 1 treatment of radioconjugate, and 51 were retreated. The level of radioconjugate administered was based on radiation-absorbed dose to critical normal organs, calculated after a "scout" dose of radioconjugate. The total injected activity, including the scout dose during the first treatment, ranged from 21 to 364 mCi (mean, 108 mCi/4 GBq). Immediate and late side-effects were minimal. Tumor size could be evaluated in 88 patients. Among these patients, the objective response rate was 25%; stable disease was observed in 53% and tumor progression in 22%. With a median follow-up of 455 days, the estimated 12- and 24-month overall survival was 46% and 23%. This multicenter study shows that 188Re lipiodol is a safe and cost-effective method to treat primary hepatocellular carcinoma via the transarterial route and requires further evaluation by treatment of greater numbers of patients. © 2008 Elsevier Inc. All rights reserved. |
| Keywords: | adult; cancer survival; treatment response; aged; aged, 80 and over; middle aged; unclassified drug; major clinical study; clinical trial; diarrhea; drug efficacy; drug safety; liver cell carcinoma; unspecified side effect; carcinoma, hepatocellular; liver neoplasms; radiation dose; follow up; liver toxicity; lung disease; vomiting; fever; cost effectiveness analysis; hypotension; dosimetry; multicenter study; stomach ulcer; radiopharmaceutical agent; radiotherapy planning, computer-assisted; tumor growth; radioisotopes; international agencies; hematologic disease; lipiodol re 188; liver pain; radiation absorption; injections, intra-arterial; iodized oil; nuclear energy; rhenium |
| Journal Title: | Seminars in Nuclear Medicine |
| Volume: | 38 |
| Issue: | 2 |
| ISSN: | 0001-2998 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2008-03-01 |
| Start Page: | S40 |
| End Page: | S45 |
| Language: | English |
| DOI: | 10.1053/j.semnuclmed.2007.10.006 |
| PUBMED: | 18243842 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 7" - "Export Date: 17 November 2011" - "CODEN: SMNMA" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work